{"filing":{"accession_number":"0001437749-26-030236","cik":"0001533040","ticker":"PHIO","company_name":"Phio Pharmaceuticals Corp.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"phio20260911_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926030236/phio20260911_8k.htm"},"events":[{"id":33179,"run_id":30499,"accession_number":"0001437749-26-030236","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Phio announced submission of a comprehensive briefing package to the FDA following completion of a Phase 1b clinical trial for PH-762, with plans for a Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, representing progress in regulatory engagement and advancement toward the next phase of clinical development. While not a specific earnings release, M\u0026A activity, or governance event, this operational/strategic milestone would affect a reasonable investor's assessment of the company's pipeline progress and regulatory trajectory.","company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36549,"accession_number":"0001437749-26-030236","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Phio announced submission of a comprehensive briefing package to the FDA following completion of a Phase 1b clinical trial for PH-762, with plans for a Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, representing progress in regulatory engagement and advancement toward the next phase of clinical development. While not a specific earnings release, M\u0026A activity, or governance event, this operational/strategic milestone would affect a reasonable investor's assessment of the company's pipeline progress and regulatory trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T13:00:53.426774+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36549,"accession_number":"0001437749-26-030236","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Phio announced submission of a comprehensive briefing package to the FDA following completion of a Phase 1b clinical trial for PH-762, with plans for a Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, representing progress in regulatory engagement and advancement toward the next phase of clinical development. While not a specific earnings release, M\u0026A activity, or governance event, this operational/strategic milestone would affect a reasonable investor's assessment of the company's pipeline progress and regulatory trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T13:00:53.426774+00:00","company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","filing_date":"2026-09-14"}]}